Multiple Myeloma Treatment Market Research Report - Global Forecast till 2027

Multiple Myeloma Treatment Market Trends, Insights and Size Analysis By Treatment (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Corticosteroids, Interferon, and Others), End User (Hospitals, Clinics, Independent Pharmacies, and Others)—Forecast till 2027

ID: MRFR/Pharma/5354-HCR | February 2023 | Region: Global | 90 Pages         

Multiple Myeloma Treatment Market Speak to Analyst Request a Free Sample

Multiple Myeloma Treatment Market

Multiple Myeloma Treatment Market is expected to exhibit a growth rate of 11.0% over the forecast period.

By Treatment Chemotherapy Radiation Therapy Stem Cell Transplant Corticosteroids Interferon Others
By End User Hospitals Clinics Independent Pharmacies Others
Key Players
Companies Profiled   Celgene Corporation   Janssen Biotech Inc.   Bristol-Myers Squibb Company   Novartis AG   Millennium Pharmaceuticals   Amgen Inc.   Genzyme Corporation   Juno Therapeutics   Johnson & Johnson   Hoffmann-La Roche Ltd.
Market Driving Forces   Rise in healthcare expenditure   Growing elderly population   High awareness about early cancer diagnosis and treatment
Request a Free Sample

Multiple Myeloma Treatment Market Overview The multiple myeloma treatment market is expected to rise steadily at a CAGR of 11.0% during the forecast period. Multiple myeloma is a plasma cell malignancy. The immune system relies on plasma cells, which are present in the bone marrow. T cells and B cells are two types of cells that make up the immune system, and they work together to combat infections and other disorders. Lymphocytes are a type of white blood cell (WBC) that play a vital role in the immune system. Lymphocytes can be found in various places throughout the body, including lymph nodes, bone marrow, the intestines, and circulation. Due to key driving factors such as increased demand for non-invasive treatments and continuous improvement in research and development efforts, medicines therapy is predicted to be the largest market during the historic forecast period. An increase in the aging population increased healthcare expenditure, and increased use of novel cancer drugs in the market is expected to drive the growth of the multiple myeloma treatment market during the forecast period, whereas increasing disease prevalence along with a growing elderly population is the primary factor driving the market growth. The future medication pipeline for multiple myeloma has also been noted as promising. In the future, other variables such as biological pharmaceuticals and stem cell therapies are projected to drive the market. The research and development activities for multiple myeloma treatment are being accelerated by the major companies in the market.

Key players:

Some of the key players in the multiple myeloma treatment market are

  • Celgene Corporation

  • Janssen Biotech, Inc.

  • Bristol-Myers Squibb Company

  • Novartis AG

  • Millennium Pharmaceuticals

  • Amgen, Inc.

  • Genzyme Corporation

  • Juno Therapeutics

  • Johnson & Johnson

  • Hoffmann-La Roche Ltd.

  • GlaxoSmithKline plc

  • AbbVie Inc.

  • Novartis AG

  • Innate Pharma SA

  • Celldex Therapeutics, Inc.

  • Onyx Pharmaceuticals

  • Pfizer

  • Takeda Pharmaceuticals

Market Segmentation:

The market of multiple myeloma treatment is further segmented into treatment types and end-users. Based on treatment types the market is segmented into chemotherapy, corticosteroids, interferon, stem cell transplant, and radiation therapy. Chemotherapy is further sub-segmented into bendamustine (treanda), cyclophosphamide (Cytoxan), doxorubicin (adriamycin), etoposide (vp-16), liposomal doxorubicin (Doxil), melphalan (Alkeran, evomela), vincristine (Oncovin). On the basis of end-user global multiple myeloma treatment market is further segmented into hospitals, clinics, rehabilitative center treatment, independent pharmacies, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The multiple myeloma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of market.   

The European multiple myeloma treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The multiple myeloma treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, North America is expected to hold the largest share in global multiple myeloma treatment market due to key driving factors such as rising prevalence of multiple myeloma, high awareness associated with early cancer diagnosis and treatment, supportive reimbursement policies, and developed healthcare infrastructure. 

Europe has been dominating the multiple myeloma treatment market owing to the faster approval rates and favorable healthcare policies and the presence of major players in this region. Higher prevalence of multiple myeloma in developed economies is driving the growth of the Europe market. 

Asia-Pacific is expected to show exponential growth due to rising awareness associated with cancer diagnosis and developing healthcare infrastructure is responsible for high accessibility to modern technology.

Furthermore, factors such as increased healthcare infrastructure and improved healthcare reimbursement policies are responsible for the growth of multiple myeloma treatment market in the Middle East and Africa.

Global Multiple Myeloma Treatment Market Share (%), by Region, 2017  

Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American Association of the neurological surgeonSegmentation

The Market of Multiple Myeloma Treatment, by Treatment

  • Chemotherapy 

  • Bendamustine (Treanda)

  • Cyclophosphamide (Cytoxan)

  • Doxorubicin (Adriamycin)

  • Etoposide

  • Liposomal doxorubicin (Doxil)

  • Melphalan (Alkeran, Evomela)

  • Vincristine (Oncovin)

  • Corticosteroids

  • Interferon

  • Stem Cell Transplant

  • Radiation Therapy

The Market of Multiple Myeloma Treatment, by End User

  • Hospitals

  • Clinics

  • Independent pharmacies

  • Others

The Market of Multiple Myeloma Treatment, by Region

  • Americas

    • North America

      • US

      • Canada

    • South America

  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe

    • Eastern Europe

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Recent Development

Sanofi SA's Sarclisa (siltuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma gained FDA approval in March 2021. UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinases (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma, received accelerated approval from the US FDA (FL).

Intended Audience

  • Manufacturers and Suppliers

  • Hospitals and clinics

  • Laboratories and Associations

  • Research institutes

Report Scope:

Report Attribute/Metric Details
  Market Size    2027: Significant Value
  CAGR   11.0% (2018 - 2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Janssen Biotech, Inc., Bristol-Myers Squibb Company, Takeda Pharmaceuticals Millennium Pharmaceuticals, Novartis AG, Genzyme Corporation, Juno Therapeutics, Johnson & Johnson, Novartis AG, Celgene Corporation, AbbVie Inc., Amgen, Inc., Innate Pharma SA, Celldex Therapeutics, Inc., GlaxoSmithKline plc, Pfizer, F. Hoffmann-La Roche Ltd., Onyx Pharmaceuticals
  Key Market Opportunities   Rising demand for non-invasive treatments, and incessant development in research and development activities.
  Key Market Drivers

  • Rise in healthcare expenditure
  • Growing elderly population
  • High awareness about early cancer diagnosis and treatment

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The multiple myeloma treatment market is projected to grow at an 11.0% CAGR between 2020-2027.

    North America is projected to command the largest share in the multiple myeloma treatment market.

    Rise in healthcare expenditure and growing elderly population is boosting market growth.

    High treatment cost may limit the multiple myeloma treatment market growth.

    Different end use industries of the multiple myeloma treatment market include independent pharmacies, hospitals, clinics, and others.